Biotest AG
Biotest AG: Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols
DGAP-News: Biotest AG / Key word(s): Disposal PRESS RELEASE – Federal Trade Commission (FTC) approved sale of Biotest US Corporation and its operating subsidiary – Grifols paid USD 286 million for the acquisition of these assets
With the approval of the FTC, the last remaining condition for the transfer of shares in the US companies was met. With the sale, Biotest AG will receive a purchase price of USD 286 million. Biotest AG has entered into the agreement on the sale of its US companies in connection with the approval by the US authority CFIUS (Committee on Foreign Investment in the United States) of the voluntary takeover bid by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisition company of Creat Group Corporation. Until the sale could be completed, Biotest AG had transferred the US companies to an US Trust. About Biotest Greenberg Traurig, LLP acted as legal advisors for the transaction. IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
01.08.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |